Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Arribas

Showing results (71-80 of 113) with videos related to

Pageof 12
Sort By:
Cancers|June 26, 2025
KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell LymphomasChiara Tarantelli, Filippo Spriano, Elisa Civanelli, et al.
The Journal of Biological Chemistry|January 28, 1999
Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activityM Roghani, J D Becherer, M L Moss, et al.
Oncogene|December 9, 2008
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicityM Scaltriti, C Verma, M Guzman, et al.
Journal of Nephrology|January 22, 2010
Different protein expression in normal and dysfunctional platelets from uremic patientsMaría Marques, Daniel Sacristán, Petra J Mateos-Cáceres, et al.
Oncogene|May 30, 2012
A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancersB Morancho, J L Parra-Palau, Y H Ibrahim, et al.
British Journal of Haematology|December 9, 2022
In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103Filippo Spriano, Chiara Tarantelli, Alberto J Arribas, et al.
Blood|November 24, 2011
Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targetsAlberto J Arribas, Yolanda Campos-Martín, Cristina Gómez-Abad, et al.
Ejhaem|September 2, 2022
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphomaFilippo Spriano, Giulio Sartori, Chiara Tarantelli, et al.
HIV Medicine|March 2, 2018
Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0L Ryom, C Boesecke, M Bracchi, et al.
Plos One|February 28, 2020
High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulationsLorena Maestre, Juan Fernando García-García, Scherezade Jiménez, et al.
Pageof 12

Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
Cancers|June 26, 2025
KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell LymphomasChiara Tarantelli, Filippo Spriano, Elisa Civanelli, et al.
The Journal of Biological Chemistry|January 28, 1999
Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activityM Roghani, J D Becherer, M L Moss, et al.
Oncogene|December 9, 2008
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicityM Scaltriti, C Verma, M Guzman, et al.
Journal of Nephrology|January 22, 2010
Different protein expression in normal and dysfunctional platelets from uremic patientsMaría Marques, Daniel Sacristán, Petra J Mateos-Cáceres, et al.
Oncogene|May 30, 2012
A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancersB Morancho, J L Parra-Palau, Y H Ibrahim, et al.
British Journal of Haematology|December 9, 2022
In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103Filippo Spriano, Chiara Tarantelli, Alberto J Arribas, et al.
Blood|November 24, 2011
Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targetsAlberto J Arribas, Yolanda Campos-Martín, Cristina Gómez-Abad, et al.
Ejhaem|September 2, 2022
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphomaFilippo Spriano, Giulio Sartori, Chiara Tarantelli, et al.
HIV Medicine|March 2, 2018
Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0L Ryom, C Boesecke, M Bracchi, et al.
Plos One|February 28, 2020
High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulationsLorena Maestre, Juan Fernando García-García, Scherezade Jiménez, et al.
Pageof 12